GLP-1 receptor agonists and DPP-4 inhibitors both harness the incretin peptide system for diabetes treatment, offering low hypoglycemia risk and weight benefits with distinct mechanisms and safety profiles.
Two approaches to one peptide systemGLP-1 RAs mimic the natural GLP-1 peptide at pharmacological levels, while DPP-4 inhibitors protect the body's own GLP-1 from breakdown — two complementary strategies with different risk-benefit profiles.
What the researchers found
Incretin-based therapies — GLP-1 receptor agonists and DPP-4 inhibitors — offer unique advantages for type 2 diabetes management: low hypoglycemia risk, effective postprandial glucose control, and weight reduction (GLP-1 RAs). Short-acting GLP-1 RAs primarily target post-meal glucose spikes, while long-acting formulations provide sustained blood sugar lowering. DPP-4 inhibitors work by preventing the breakdown of natural GLP-1 peptide. Safety considerations include pancreatitis risk, C-cell hyperplasia concerns, renal effects, and GI side effects (especially in older adults).
Why it matters
This review captures the incretin therapy landscape at a pivotal time — when GLP-1 drugs and DPP-4 inhibitors were transitioning from novel agents to mainstream diabetes treatments. Understanding both drug classes and their different approaches to harnessing the incretin peptide system (mimicking GLP-1 directly vs. preventing its breakdown) provides essential context for the peptide drug revolution that followed.
The numbers in context
Two drug classes covered · GLP-1 RAs: short-acting and long-acting · DPP-4 inhibitors: oral · low hypoglycemia risk · weight reduction (GLP-1 RAs) · GI side effects most common · CV outcome studies ongoing at time of publication
How the study worked
Clinical review published in Medical Clinics of North America summarizing the pharmacology, clinical efficacy, safety profile, and practical prescribing considerations for incretin-based therapies in type 2 diabetes.
Who was studied
Review covering adults with type 2 diabetes treated with incretin-based therapies
What this study cannot tell us
Published in 2015, before the major cardiovascular outcome trials were completed. Semaglutide and tirzepatide were not yet available. The review predates the expansion of GLP-1 RAs into obesity, cardiovascular risk reduction, and other indications. Safety concerns discussed (pancreatitis, C-cell tumors) have since been largely resolved by larger studies.
How to read the evidence
This is a clinical review synthesizing established evidence from multiple clinical trials and treatment guidelines. The underlying evidence is high-quality, though published before pivotal cardiovascular outcome trials were completed.
When this study was published
Published in 2015, this review predates the GLP-1 drug explosion (semaglutide obesity approval 2021, tirzepatide 2022, cardiovascular outcome data). While the basic pharmacology remains accurate, the clinical landscape has transformed significantly since publication.
The bigger picture
This 2015 review captures the incretin therapy field at an inflection point — before the explosive growth of GLP-1 drugs for obesity, cardiovascular protection, and beyond. The framework it establishes (GLP-1 mimicry vs. GLP-1 preservation) remains foundational for understanding the entire class. Since then, the field has expanded dramatically with semaglutide becoming one of the most-prescribed drugs globally and tirzepatide (a dual GIP/GLP-1 agonist) adding a new dimension.
Questions still open
- Has the cardiovascular safety of incretin-based therapies been confirmed by the outcome trials that were pending at publication?
- How does the newer dual GIP/GLP-1 agonist tirzepatide compare to the GLP-1 RAs and DPP-4 inhibitors reviewed here?
- Are DPP-4 inhibitors still relevant now that GLP-1 RAs have expanded to obesity and cardiovascular indications?
Common questions
What is the difference between GLP-1 agonists and DPP-4 inhibitors?
Why do incretin-based therapies have a lower risk of causing low blood sugar?
Read the original research
Incretin-based therapies.
The Medical clinics of North America, 99(1), 107-29
Citation
Neumiller, Joshua J. (2015). Incretin-based therapies.. The Medical clinics of North America, 99(1), 107-29. https://doi.org/10.1016/j.mcna.2014.08.013